TickerFacts.

Eupraxia Pharmaceuticals Inc. (EPRX): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$28.55M
Year ended 2025-12-31
2022-12-31: -$14.40M2023-12-31: -$20.75M2024-12-31: -$29.99M2025-12-31: -$28.55M-$28.55M
2022-12-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31-$28.55Mn/m2026-03-13, From 2025-01-01
2024-12-31-$29.99Mn/m2026-03-13, From 2024-01-01
2023-12-31-$20.75Mn/m2025-03-20, From 2023-01-01
2022-12-31-$14.40Mn/a2024-04-01, From 2022-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Eupraxia Pharmaceuticals Inc. (EPRX)2025-12-31-$28.55Mn/m
Abbott Laboratories (ABT)2025-12-31$9.57B+11.8%
Bristol Myers Squibb Co (BMY)2025-12-31$14.16B-6.8%
TherapeuticsMD, Inc. (TXMD)2025-12-31$2.45M+109.7%
Eli Lilly & Co (LLY)2025-12-31$16.81B+90.7%
Pfizer Inc (PFE)2025-12-31$11.70B-8.2%
Johnson & Johnson (JNJ)2025-12-28$24.53B+1.1%
Nature's Sunshine Products Inc (NATR)2025-12-31$35.32M+39.6%
Merck & Co., Inc. (MRK)2025-12-31$16.47B-23.3%

Compare EPRX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗